Aspen Aerogels (ASPN) opened Q1 2026 with total revenue of US$37.9 million and a basic EPS loss of US$0.29, while trailing twelve month revenue stood at US$230.3 million against a TTM basic EPS loss of US$1.36. Over recent quarters the company has seen quarterly revenue range from US$41.3 million to US$78.7 million, with basic EPS moving between a loss of US$3.67 and a profit of US$0.14. This gives investors a wide spread of outcomes to weigh against the current report. With losses still present and revenue forecasts pointing to around 19.1% annual growth, the focus now is on how quickly margins can stabilize from here.

See our full analysis for Aspen Aerogels.

With the headline numbers on the table, the next step is to see how this latest earnings snapshot lines up against the widely followed risk and reward narratives around Aspen Aerogels and whether those stories still hold up.

Trailing losses still large at US$112 million

• On a trailing twelve month view, Aspen Aerogels reported US$230.3 million of revenue and a net loss of US$112.0 million, with basic EPS at a loss of US$1.36.
• Critics looking at the bearish side often point to the combination of ongoing losses and no forecast path to profitability over the next three years, and the trailing numbers support that concern as net losses stayed in the hundreds of millions over recent periods and EPS on this basis remains firmly negative.

Q1 loss narrows versus recent quarters

• Q1 2026 net loss came in at US$23.7 million with a basic EPS loss of US$0.29, compared with recent quarters that saw losses of US$72.9 million in Q4 2025 and US$301.2 million in Q1 2025.
• For those taking a more bullish angle, what stands out is that even though Aspen is still unprofitable, the most recent quarterly loss is materially smaller than some of the very large losses reported over the past year. Investors may weigh this against the forecast that the company is expected to remain loss making for at least the next three years.

Growth story vs premium P/S valuation

• Revenue is forecast to grow around 19.1% per year while the stock trades on a P/S of about 1.8x, compared with 0.8x for peers and 1.2x for the wider US chemicals industry, and the current share price of US$5.12 sits well below a DCF fair value of about US$111.77 from the provided model.
• Bears highlight that paying a premium P/S multiple for a company that is unprofitable and expected to stay that way for at least three years is risky, while the bullish counterpoint is that the same data set shows a very large gap between the share price and the cited DCF fair value. Investors are weighing a forecast growth rate above the US market against both the richer P/S ratio and the persistence of losses.

Some investors will want to see how this mix of fast forecast revenue growth, ongoing losses, and a wide gap to DCF fair value fits into the broader community view on the stock, which is where the latest narrative work can help connect these numbers to a longer term story about Aspen Aerogels.Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Aspen Aerogels's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Seeing both risks and rewards in this story, it makes sense to look at the underlying data yourself and move quickly to form your own view. You can start with the 2 key rewards and 2 important warning signs

See What Else Is Out There

Aspen Aerogels is still posting sizeable losses, has no forecast path to profitability over the next three years, and trades on a premium P/S multiple.

If that mix of ongoing losses and valuation pressure feels uncomfortable, you can immediately focus on steadier candidates by screening for 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.